Emerging Therapeutic Options in Age-Related Macular Degeneration | Zendy

Giuseppe Querques | Zendy; Vittorio Capuano | Zendy; Pietro Frascio | Zendy; Francesco Bandello | Zendy; Eric H. Souied | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emerging Therapeutic Options in Age-Related Macular Degeneration

Author(s) -

Giuseppe Querques,

Vittorio Capuano,

Pietro Frascio,

Francesco Bandello,

Eric H. Souied

Publication year - 2015

Publication title -

ophthalmic research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.893

H-Index - 54

eISSN - 1423-0259

pISSN - 0030-3747

DOI - 10.1159/000379754

Subject(s) - macular degeneration , medicine , pegaptanib , bevacizumab , vascular endothelial growth factor , drug , clinical trial , ophthalmology , pharmacology , vegf receptors , ranibizumab , chemotherapy

Intravitreal injection of anti-VEGF drugs currently represents the standard of treatment for exudative age-related macular degeneration. Several therapeutic options including steroids, inhibitors of complement factors, anti-platelet-derived growth factor agents, new anti-VEGF drugs, designed ankyrin repeat proteins, sustained drug delivery devices as an alternative to intravitreal injections and encapsulated cell technology are the objects of several studies and trials worldwide in association with anti-VEGF therapy or not. Expectations are that such efforts will help overcome limitations of current therapy with anti-VEGF, extending the duration of effects and hopefully contributing to the regression of neovascular lesions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research